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A fascinating and unexpected link between ultraviolet (UV)B
and adipose tissue has been proposed by the pioneering origi-
nal article of Kim et al.,1 published in the current issue of the
BJD. It is well established that adipose tissue is not a mere inert
fat-storage facility, but is an endocrine organ secreting multiple
mediators, named ‘adipokines’; furthermore, these adipokines
are able to contribute to systemic inflammation.2 These media-
tors are represented by conventional adipokines, such as adipo-
nectin, leptin, visfatin and chemerin. Moreover, there is also a
wide array of adipocytokines and adipochemokines secreted
not all exclusively by adipocytes. Indeed, adipose tissue also
contains endothelial cells, fibroblasts, macrophages, myeloid
cells and T cells,3 which contribute to their production.
Adipokines are able to orchestrate the interaction between
metabolic and immune systems. The mediators released either
by adipocytes or by other cells resident in the adipose tissue
may have a significant role in several autoimmune skin dis-
eases, acting on immune cells and keratinocytes.4 Subcutaneous
(SC) and visceral fat are different in composition, metabolism
and functions. Some studies have shown that a decrease in SC
fat as well as an increase in visceral fat resulted in an aug-
mented risk for metabolic syndrome.5,6 These events are inter-
related because the age-related impairment of the lipid storage
capability of SC fat promotes excess visceral fat, leading to an
altered metabolic homeostasis.5,6 As UVB cannot cross the der-
mis, SC fat had been considered to be relatively unaffected by
UVB exposure. However, the recent concept of bidirectional
cross-talk between skin and adipose tissue highlights the possi-
bility of a dynamic interplay.7 The authors have previously
reported that UVB-irradiated skin modulated SC fat metabolism
via the release of pro-inflammatory factors.8,9 However, how
these factors could influence SC fat activity still remained
unclear. In their current paper, Kim et al.1 have shown for the
first time that adipocytes treated with UVB-irradiated ker-
atinocytes and fibroblasts produce specific adipochemokines,
including C–X–C chemokines such as ENA-78, and C–C
chemokines such as MIP-3a and RANTES, which impair
triglyceride synthesis via downregulation of lipogenic enzymes.
Moreover, they have confirmed the results in vivo comparing
sun-exposed skin with sun-protected skin, exploring also the
ability of UVB irradiation to induce macrophage infiltration
into adipose tissue. Overall, the data from the article by Kim
et al.1 suggest that the bridge between UVB irradiation and SC
fat is represented by the skin with a crucial role played by
fibroblasts and keratinocytes. This manuscript has demonstrated
that UVB exerts pro-inflammatory effects on SC adipose tissue.
These results may help to explain why phototherapy does not
reduce the risk of cardiovascular events in patients with psoria-
sis, in contrast to benefits described for systemic therapies.10
Additional studies are needed to investigate UVB effects on
visceral fat tissue, as the latter is mainly associated with a
higher risk of cardiovascular events.
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The concept of ‘collision tumours’ is a well-accepted occur-
rence in dermatopathology.1 In such scenarios, two different
tumours are juxtaposed. Most cases are considered to have col-
lided by chance but some may be more than coincidental,
involving similar cell lineages or particular combinations of
disease entities.2 In clinical dermatology, the simultaneous
overlap of two dermatoses is perhaps less appreciated and also
may be attributed to randomness. But when such double enti-
ties become repeated phenomena, as is the case for hidradeni-
tis suppurativa (HS) and Dowling–Degos disease (DDD), the
questions change to why and how might this be happening?
The co-occurrence of HS and DDD was first mentioned in
1990,3 and several further reports have followed. In this issue
of the BJD, Pavlovsky et al.4 describe four more individuals
with HS–DDD. This study was also able to identify a founder
mutation in PSENEN, which encodes a component of the
c-secretase complex. Mutations in PSENEN have previously
been found in some other reports of HS–DDD as well as a
small number of cases of HS. But how does PSENEN gene
pathology tie in with the double clinical pathology?
The answer appears to lie in the consequences of altered
c-secretase complex functioning.
The c-secretase complex is a key regulator of the canonical
Notch signalling pathway. Notably, intramembrane cleavage of
Notch by c-secretase releases its major intracellular signalling
domain.5 Notch signalling has been implicated in differentia-
tion of both interfollicular and follicular epithelium, the hair
growth cycle, follicular cyst development, sebaceous gland dif-
ferentiation and melanocyte homeostasis – a combination of
downstream effects that begins to link the clinicopathological
anomalies of both HS and DDD. To address the possibility of
aberrant Notch, Pavlovsky et al.4 designed a Notch reporter
assay and in the keratinocytes of their patient with HS–DDD
they were able to show a reduction in Notch signalling (and in
other associated Notch effector genes) that provides some
rationale for the clinical collision of HS and DDD.
Nonetheless, some issues remain unresolved. It is unclear
why mutations in PSENEN can cause either HS–DDD or isolated
HS or, as also reported here as an original observation, iso-
lated DDD. The particular clinical features do not appear to be
the result of specific mutations as precisely the same genetic
variant can have diverse phenotypic consequences. Perhaps
modifier genes, currently unknown, may have some influence.
What we do know, thanks to this study, is that the clinical
and tissue impact of the observed pathology in HS–DDD is
likely to reflect the direct consequences of aberrant Notch sig-
nalling. These data provide new insights into this particular
‘clinical collision’ and potentially offer new opportunities for
improving patient management in the future, both preventa-
tive and therapeutic.
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Drug survival or persistence studies are best explained as ‘the
period of time during which a given drug continues to be an
adequate treatment for a specific patient’,1 and provide clini-
cally relevant information regarding biological treatments in
the real-world setting.2
Efficacy and/or adverse events can affect the success or fail-
ure of a biologic. A second-line biologic could bias data with
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